Oncology
GSK shares results from phase 3 trial for Blenrep for treatment of multiple myeloma
March 7, 2024Research and Development Blenrep, GSK, Oncology, clinical trial, multiple myeloma
GSK has announced positive results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial which assesses Blenrep (belantamab …
GSK’s Jemperli recommended by NICE for endometrial cancer treatment
March 5, 2024Medical Communications GSK, Jemperli, NICE, Oncology, endometrial cancer
GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of Jemperli (dostarlimab) …
FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment
March 4, 2024Medical Communications FDA, Johnson & Johnson, NSCLC, Oncology, Rybrevant
Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved Rybrevant (amibantamab-vmjw) following a priority …
EMA validates two applications for datopotamab deruxtecan for cancer treatments
March 4, 2024Medical Communications CHMP, Daiichi Sankyo, EMA, Oncology, datopotamab deruxtecan
AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications (MAAs) for AstraZeneca and Daiichi …
Cardiff Oncology doses first patient in colorectal cancer trial
March 1, 2024Research and Development Cardiff Oncology, Oncology, clinical trial, colorectal cancer
Cardiff Oncology has announced that it has dosed the first patient in its randomised first-line phase 2 trial, CRDF-004, for …
Viracta Therapeutics completes enrolment for T-cell lymphoma cohort in NAVAL-1 trial
March 1, 2024Medical Communications Oncology, Viracta Therapeutics, lymphoma
Viracta Therapeutics has announced that it has completed stage 2 enrolment into the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) …
AbbVie and Tentarix collaborate on oncology and immunology treatments
February 23, 2024Research and Development AbbVie, Oncology, collaboration, immunology
AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on the discovery and development of …
FDA accepts BLA for Regeneron’s linvoseltamab for Priority Review
February 22, 2024Medical Communications FDA, Oncology, Regeneron, bla, priority review
Regeneron Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for …
AstraZeneca’s Tagrisso approved by FDA for lung cancer treatment
February 19, 2024Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Tagrisso for the treatment of adult patients …
Iovance’s Amtagvi gains FDA accelerated approval for melanoma treatment
February 19, 2024Medical Communications Iovance, Oncology, accelerated approval, melanoma
Iovance Biotherapeutics has announced that the US Food and Drug Administration (FDA) has approved Amtagvi (lifileucel) suspension for intravenous infusion …
Astellas and Kelonia Therapeutics enter agreement for development of immuno-oncology therapeutics
February 16, 2024Research and Development Astellas Pharma, Kelonia Therapeutics, Oncology, collaboration, immuno-oncology
Astellas Pharma and Kelonia Therapeutics have announced that Xyphos Biosciences (a wholly owned subsidiary of Astellas) and Kelonia have entered …
Freenome raises $254m funding for early cancer detection platform
February 16, 2024Research and Development Diagnostics, Freenome, Oncology, cancer detection, funding
Freenome has announced that it has raised $254m from new and existing investors, intended to be used for the advancement …
FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma treatment
February 14, 2024Medical Communications FDA, Oncology, Onivyde, ipsen, pancreatic adenocarcinoma
Ipsen has announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for …
BioNTech and Autolus announce CAR T-cell therapy collaboration
February 9, 2024Research and Development Autolus, BioNTech, CAR T-cell, Oncology, collaboration
BioNTech and Autolus Therapeutics have announced that they have entered a strategic collaboration intended to further both companies’ autologous CAR …
Regeneron’s linvoseltamab gains EMA filing acceptance for R/R MM treatment
February 5, 2024Medical Communications EMA, Oncology, Regeneron, linvoseltamab, multiple myeloma
Regeneron Pharmaceuticals has announced that the European Medicines Agency (EMA) has accepted for review its Marketing Authorisation Application (MAA) for …
Latest content
FibroFind appoints Lee Borthwick as CEO
